Answers are grounded in this paper and cite their sources.
A series of novel 2-arylbenzoxazoles that upregulate the production of utrophin in murine H2K cells, as assessed using a luciferase reporter linked assay, have been identified. This compound class appears to hold considerable promise as a potential treatment for Duchenne muscular dystrophy. Following the delineation of structure-activity relationships in the series, a number of potent upregulators were identified, and preliminary ADME evaluation is described. These studies have resulted in the identification of 1, a compound that has been progressed to clinical trials.
No takes yet. Share an insight, caveat, or question.
Chancellor et al. (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: